We use Google Analytics to see which pages are read and how the site is used, so we know what to improve. This only runs if you accept. See our privacy notice for details.

Dáil

›

Health Service Executive

Summary

The Minister said processing times vary too widely for a meaningful average, while the HSE aims to review new medicines and uses within 180 days.

1744. Deputy Ryan O'Meara asked the Minister for Health the average processing time for a complete pricing and reimbursement application with the HSE. [75578/26]

Comment on this

The Government recognises the importance of timely access for patients to new medicines.

Under the Health (Pricing and Supply of Medical Goods) Act 2013 the HSE has sole statutory responsibility for decisions on pricing and reimbursement of medicines under the community drugs schemes.

HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds. There are formal processes which govern applications for the pricing and reimbursement of medicines, and new uses of existing medicines, to be funded and / or reimbursed.

Reimbursement is for licenced indications which have been granted market authorisation either by the European Medicines Agency (EMA) or by the Health Products Regulatory Authority (HPRA). Once a licence is granted a company must then apply to the HSE for a medicine to be reimbursed in its licenced indication.

Once the process has begun, applicants must continue to engage throughout the process to ensure that the necessary evidence is available for the HSE to carry out its statutory role as a decision-maker with respect to the reimbursement of new medicines, in accordance with the Act. The Act specifies nine criteria which must be considered. These include the health needs of the public and the clinical need for the medicine. All these factors, taken together, allow the HSE to make an informed decision on new medicines.

The processing time for pricing and reimbursement applications vary considerably depending on the nature and complexity of the application.

Factors influencing the overall timeframe include whether the medicine requires a full pharmacoeconomic assessment (Health Technology Assessment (HTA)) after a Rapid Review is conducted by the National Centre for Pharmacoeconomics, the complexity of the clinical and economic evidence submitted, the need for engagement with the applicant during the assessment process, and any subsequent pricing or commercial negotiations.

The HSE seeks to process all applications as efficiently as possible while ensuring that decisions are informed by robust clinical and economic evidence and represent value for money for patients.

Consequently, the duration of the process can vary significantly on a case-by-case basis and a single average processing time would not provide a meaningful representation of the pricing and reimbursement process for all drugs.

As outlined in the Framework Agreements on the Supply and Pricing of Medicines (FASPM) 2026-2029, the HSE is committed to achieving a 180-day review of new medicines and new uses of existing medicines.

Comment on this